VBL Presents New Data on MOSPD2 Antibodies as Potential Treatment for NASH and Colitis at DDW

NEXT STORY
Allogene Therapeutics Reports First Quarter 2020 Financial Results
PREV STORY
ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved in numerous neurodegenerative diseases, including ALS
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)

author_avatar
NASDAQ Market News

Cellectis’ Annual Shareholders’ General Meeting to be Held on June 29, 2020

author_avatar
NASDAQ Market News

HealthLynked Corp. Announces the Launch of New Website

author_avatar
NASDAQ Market News